JP6681922B2 - イブルチニブの製造方法 - Google Patents
イブルチニブの製造方法 Download PDFInfo
- Publication number
- JP6681922B2 JP6681922B2 JP2017560860A JP2017560860A JP6681922B2 JP 6681922 B2 JP6681922 B2 JP 6681922B2 JP 2017560860 A JP2017560860 A JP 2017560860A JP 2017560860 A JP2017560860 A JP 2017560860A JP 6681922 B2 JP6681922 B2 JP 6681922B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- potassium
- group
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 title claims description 34
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 title claims description 33
- 229960001507 ibrutinib Drugs 0.000 title claims description 33
- 238000004519 manufacturing process Methods 0.000 title claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 104
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 38
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 27
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 21
- 239000003054 catalyst Substances 0.000 claims description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 16
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 13
- 101150003085 Pdcl gene Proteins 0.000 claims description 13
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 13
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 12
- 235000011009 potassium phosphates Nutrition 0.000 claims description 12
- 238000006751 Mitsunobu reaction Methods 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- -1 hydride potassium Chemical compound 0.000 claims description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 11
- 235000011181 potassium carbonates Nutrition 0.000 claims description 11
- 239000012046 mixed solvent Substances 0.000 claims description 10
- 239000011736 potassium bicarbonate Substances 0.000 claims description 9
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 9
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 9
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 9
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 9
- HPYNZHMRTTWQTB-UHFFFAOYSA-N 2,3-dimethylpyridine Chemical compound CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 8
- 239000007810 chemical reaction solvent Substances 0.000 claims description 8
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 8
- 239000012312 sodium hydride Substances 0.000 claims description 8
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 8
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims description 7
- 229910000105 potassium hydride Inorganic materials 0.000 claims description 7
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 6
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 claims description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims description 4
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 claims description 4
- 235000011056 potassium acetate Nutrition 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- 235000017550 sodium carbonate Nutrition 0.000 claims description 4
- 239000001488 sodium phosphate Substances 0.000 claims description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 4
- 235000011008 sodium phosphates Nutrition 0.000 claims description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
- AEDZKIACDBYJLQ-UHFFFAOYSA-N ethane-1,2-diol;hydrate Chemical compound O.OCCO AEDZKIACDBYJLQ-UHFFFAOYSA-N 0.000 claims description 3
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 claims description 3
- VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 claims description 2
- NKMKDPVCESDJCN-UHFFFAOYSA-N 3-[di(propan-2-yl)carbamoylimino]-1,1-di(propan-2-yl)urea Chemical compound CC(C)N(C(C)C)C(=O)N=NC(=O)N(C(C)C)C(C)C NKMKDPVCESDJCN-UHFFFAOYSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 230000003796 beauty Effects 0.000 claims 10
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 claims 2
- USVVENVKYJZFMW-ONEGZZNKSA-N (e)-carboxyiminocarbamic acid Chemical compound OC(=O)\N=N\C(O)=O USVVENVKYJZFMW-ONEGZZNKSA-N 0.000 claims 1
- QLRABMIWBLRFCO-UHFFFAOYSA-N 4,7-dimethyl-5,6-dihydro-1,2,4,7-tetrazocine-3,8-dione Chemical compound CN1CCN(C)C(=O)N=NC1=O QLRABMIWBLRFCO-UHFFFAOYSA-N 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229940093932 potassium hydroxide Drugs 0.000 claims 1
- DBCAVMLQRAABFF-UHFFFAOYSA-M potassium;carbonic acid;hydrogen carbonate Chemical compound [K+].OC(O)=O.OC([O-])=O DBCAVMLQRAABFF-UHFFFAOYSA-M 0.000 claims 1
- 229940083608 sodium hydroxide Drugs 0.000 claims 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 claims 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 43
- 239000000243 solution Substances 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 229910001873 dinitrogen Inorganic materials 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 19
- 239000002585 base Substances 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- 239000008346 aqueous phase Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000005587 bubbling Effects 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 238000006069 Suzuki reaction reaction Methods 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 150000007529 inorganic bases Chemical class 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 239000003880 polar aprotic solvent Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- UIFGGABIJBWRMG-FMQUCBEESA-N (4-chlorophenyl)methyl (ne)-n-[(4-chlorophenyl)methoxycarbonylimino]carbamate Chemical compound C1=CC(Cl)=CC=C1COC(=O)\N=N\C(=O)OCC1=CC=C(Cl)C=C1 UIFGGABIJBWRMG-FMQUCBEESA-N 0.000 description 2
- KFXUHRXGLWUOJT-UHFFFAOYSA-N (4-phenoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1=CC=CC=C1 KFXUHRXGLWUOJT-UHFFFAOYSA-N 0.000 description 2
- 0 *C1=N*([C@](CCC2)CN2C(C=C)=O)c2ncnc(N)c12 Chemical compound *C1=N*([C@](CCC2)CN2C(C=C)=O)c2ncnc(N)c12 0.000 description 2
- GZQVGSRUUTUJNG-UHFFFAOYSA-N 3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=NNC(Br)=C12 GZQVGSRUUTUJNG-UHFFFAOYSA-N 0.000 description 2
- FRXLFVNGTPQFEJ-UHFFFAOYSA-N 3-bromopropanoyl bromide Chemical compound BrCCC(Br)=O FRXLFVNGTPQFEJ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- QJIMTLTYXBDJFC-UHFFFAOYSA-N (4-methylphenyl)-diphenylphosphane Chemical compound C1=CC(C)=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJIMTLTYXBDJFC-UHFFFAOYSA-N 0.000 description 1
- HQAIUXZORKJOJY-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=NNC(I)=C12 HQAIUXZORKJOJY-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- RYAQFHLUEMJOMF-UHFFFAOYSA-N 4-phenoxybenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OC1=CC=CC=C1 RYAQFHLUEMJOMF-UHFFFAOYSA-N 0.000 description 1
- LHCPRYRLDOSKHK-UHFFFAOYSA-N 7-deaza-8-aza-adenine Chemical compound NC1=NC=NC2=C1C=NN2 LHCPRYRLDOSKHK-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 description 1
- QDTUWIBSSHHSKF-SECBINFHSA-N Bc1n[n]([C@H](CCC2)CN2C(OC(C)(C)C)=O)c2ncnc(N)c12 Chemical compound Bc1n[n]([C@H](CCC2)CN2C(OC(C)(C)C)=O)c2ncnc(N)c12 QDTUWIBSSHHSKF-SECBINFHSA-N 0.000 description 1
- NUNMQUDOHSXMPE-ZCFIWIBFSA-N Bc1n[n]([C@H]2CNCCC2)c2ncnc(N)c12 Chemical compound Bc1n[n]([C@H]2CNCCC2)c2ncnc(N)c12 NUNMQUDOHSXMPE-ZCFIWIBFSA-N 0.000 description 1
- UIJXHKXIOCDSEB-QMMMGPOBSA-N CC(C)(C)OC(N(CCC1)C[C@H]1O)=O Chemical compound CC(C)(C)OC(N(CCC1)C[C@H]1O)=O UIJXHKXIOCDSEB-QMMMGPOBSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- XXBJBOWLTYFSGL-MRVPVSSYSA-N Nc1c2c(Br)n[n]([C@H](CCC3)CN3C(CCBr)=O)c2ncn1 Chemical compound Nc1c2c(Br)n[n]([C@H](CCC3)CN3C(CCBr)=O)c2ncn1 XXBJBOWLTYFSGL-MRVPVSSYSA-N 0.000 description 1
- KKXJSUAAPOQJSI-ZCFIWIBFSA-N Nc1c2c(Br)n[n]([C@H]3CNCCC3)c2ncn1 Chemical compound Nc1c2c(Br)n[n]([C@H]3CNCCC3)c2ncn1 KKXJSUAAPOQJSI-ZCFIWIBFSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000350481 Pterogyne nitens Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
塩基及び触媒の存在下で式3化合物と式4化合物とを反応させてイブルチニブを生成するステップ2
(但し、X1はそれぞれ独立にCl、Br及びI、好ましくはCl及びBrからなる群より選ばれ、X2はそれぞれ独立にCl及びBrからなる群より選ばれ、R’は
塩基の存在下で式8化合物と式2−1化合物とを反応させてイブルチニブを生成するステップ2
(但し、X1はそれぞれ独立にCl、Br及びI、好ましくはCl及びBrからなる群より選ばれ、X2はそれぞれ独立にCl及びBrからなる群より選ばれる。)
塩基及び触媒の存在下で式3化合物と式4化合物とを反応させてイブルチニブを生成するステップ2
(但し、X1はそれぞれ独立にCl、Br及びI、好ましくはCl及びBrからなる群より選ばれ、X2はそれぞれ独立にCl及びBrからなる群より選ばれ、R’は
塩基の存在下で式8化合物と式2−1化合物とを反応させてイブルチニブを生成するステップ2
(但し、X1はそれぞれ独立にCl、Br及びI、好ましくはCl及びBrからなる群より選ばれ、X2はそれぞれ独立にCl及びBrからなる群より選ばれる。)
式1化合物を製造するために、光延反応試薬の存在下で式5化合物と式6化合物とを反応させて式7化合物を生成し、次に、酸の存在下で式7化合物に対して保護基を除去して式1化合物を生成するステップをさらに含む。
2.鈴木反応に使用された触媒の投入量が、先行文献で報道した投入量よりもずっと少なく、且つ1〜5時間反応するだけで原料の転化率は100%に達する。
3.アシル化反応を行った後に鈴木反応を発生させる場合、鈴木反応を発生させると同時にハロゲン化水素を除去する反応が起こり、それにより、反応ステップや生成物における不純物含有量を減少させ、全収率を向上させる。
4.式5化合物を原料として、先ず光延反応を行うことにより、原料の転化率を著しく向上させ、さらに、反応生成物を反応液から直接に析出できることから、光延反応の生成物をクロマトグラフィー法で精製する必要があるという従来技術の欠点を解決する。特にXがBrである場合、生成物の収率を向上させ、精製方法を簡素化させるとともに、原料コストを削減させる。
5.式1化合物と式4化合物とを反応させて式8化合物を製造するステップでは、触媒の投入量が、先行文献で報道された投入量よりも遥かに少なく、且つ、1〜5時間反応させるのみで原料の転化率が100%に達すことができ、反応中に生じた不純物が極めて少量であるので、生成物が単に対応の塩に形成させるのみで精製でき、生成物の純度が高い。
m/z (MH+) 351, 1H NMR (400MHz, DMSO) δ 1.56 − 1.59 (m, 1H), 1.88 − 1.99 (m, 1H), 2.05 − 2.22 (m, 3H), 2.91 (m, 0.5H) & 3.59−3.62 (m, 0.5H), 3.07 − 3.19 (m, 1H), 4.05 − 4.08 (m, 0.5H) & 4.51 − 4.57 (m, 0.5H), 4.60 − 4.63 (m, 1H), 5.61 − 6.15 (dd, 2H), 6.69 − 6.88 (m, 1H), 8.23 (s, 1H)。
m/z ( MH+ ), 1H NMR(400 MHz, DMSO) δ 8.22 (s, 1H), 6.82 − 6.86 (m, 1H), 6.11 − 6.15 (m, 1H), 5.63 − 5.72 (m, 1H), 4.63 − 4.69 (m, 1H), 4.05 − 4.19 (m, 0.5H), 4.59 − 4.63 (m, 0.5H), 3.84 (m, 0.5H), 3.10 − 3.16 (m, 1H), 1.85 − 1.94 (m, 2H), 2.04 − 2.08 (m, 1H), 1.55 − 1.58 (m, 1H)。
m/z (MH+) 1H NMR (400 MHz, DMSO) δ 8.24 (s, 1H), 4.47 − 4.56 (m, 1H), 4.00 − 4.04 (m, 1H), 4.69 (m, 0.5H), 4.21 − 4.27 (m, 0.5H), 3.80 − 3.82 (m, 0.5H), 3.51 − 3.57 (m, 0.5H), 3.76 − 3.80 (m, 1H), 2.70 − 3.14 (m, 4H), 2.05 − 2.16 (m, 2H), 1.48 − 1.64 (m, 2H)。
m/z (MH+) 1H NMR (400 MHz, DMSO) δ 8.31 (s, 1H), 4.71 − 4.76 (m, 1H), 4.48 − 4.59 (m, 1H), 4.20 − 4.23 (m, 0.5H), 4.00 − 4.02 (m, 0.5H), 3.86 − 3.89 (m, 0.5H), 3.51 − 3.55 (m, 0.5H), 3.55 − 3.67 (m, 1H), 2.81 − 3.17 (m, 1H), 2.06 − 2.21 (m, 2H), 1.81 − 1.91 (m, 1H), 1.46 − 1.68 (m, 1H)。
m/z (MH+), 1H NMR (400 MHz, DMSO) δ 8.23 (s, 1H), 4.66 − 4.71 (m, 0.5H), 4.47 − 4.58 (m, 1H), 4.21 − 4.24 (m, 0.5H), 3.99 − 4.03 (m, 0.5H), 3.87 − 3.90 (m, 0.5H), 3.76 − 3.82 (m, 2H), 2.71 − 3.15 (m, 4H), 1.99 − 2.21 (m, 2H), 1.80 − 1.89 (m, 1H), 1.48 − 1.64 (m, 1H)。
m/z ( MH+ ), 1H NMR (400 MHz, DMSO) δ 8.23 (s, 1H), 4.69 (m, 0.5H), 4.47 − 4.55 (m, 1H), 4.20 − 4.24 (m, 0.5H), 3.97 − 3.98 (m, 0.5H), 3.86 − 3.89 (m, 0.5H), 3.52 − 3.67 (m, 2H), 2.83 − 3.12 (m, 4H), 2.06 − 2.19 (m, 2H), 1.86 − 1.89 (m, 1H), 1.64 − 1.84 (m, 1H)。
Claims (10)
- 前記ステップ1において、前記塩基は、炭酸カリウム、炭酸ナトリウム、炭酸水素ナトリウム、炭酸水素カリウム、水酸化ナトリウム、水酸化カリウム、水素化カリウム、水素化ナトリウム、トリエチルアミン、ジメチルピリジン、ジイソプロピルエチルアミン、又は1,8−ジアザビシクロ[5.4.0]ウンデカ−7−エンであり、及び/又は、前記ステップ1において、反応溶媒は、テトラヒドロフラン、2−メチルテトラヒドロフラン、N,N−ジメチルホルムアミド、アセトニトリル、及びアセトンからなる群より選ばれ、及び/又は、前記ステップ2において、前記触媒は、Pd(PPh3)4、PdCl2(PPh3)2、PdCl2(PhCN)2、Pd(OAc)2、Pd/C、及びPdCl2(dppf)2からなる群より選ばれ、及び/又は、前記ステップ2において、前記塩基は、炭酸カリウム、炭酸ナトリウム、炭酸セシウム、酢酸カリウム、酢酸ナトリウム、リン酸カリウム、リン酸ナトリウム、炭酸水素ナトリウム、炭酸水素カリウム、水酸化ナトリウム、水酸化カリウム、水素化ナトリウム、又は水素化カリウムであり、及び/又は、前記ステップ2において、反応溶媒は、テトラヒドロフラン、1,4−ジオキサン、アセトニトリル、アセトン、N,N−ジメチルホルムアミド(DMF)、ジメチルスルホキシド、N−メチルピロリドン、又はエチレングリコールジメチルエーテルと水との混合溶媒である、請求項1に記載のイブルチニブの製造方法。
- 前記ステップ1において、前記触媒は、Pd(PPh3)4、PdCl2(PPh3)2、PdCl2(PhCN)2、Pd(OAc)2、Pd/C、及びPdCl2(dppf)2からなる群より選ばれ、及び/又は、前記ステップ1において、前記塩基は、炭酸カリウム、炭酸ナトリウム、炭酸セシウム、酢酸カリウム、酢酸ナトリウム、リン酸カリウム、リン酸ナトリウム、炭酸水素ナトリウム、炭酸水素カリウム、水酸化ナトリウム、水酸化カリウム、水素化ナトリウム、又は水素化カリウムであり、及び/又は、前記ステップ1において、反応溶媒は、テトラヒドロフラン、1,4−ジオキサン、アセトニトリル、アセトン、N,N−ジメチルホルムアミド、ジメチルスルホキシド、N−メチルピロリドン、又はエチレングリコールジメチルエーテルと水との混合溶媒であり、及び/又は、前記ステップ2において、前記塩基は、炭酸カリウム、炭酸ナトリウム、炭酸水素ナトリウム、炭酸水素カリウム、水酸化ナトリウム、水酸化カリウム、水素化カリウム、水素化ナトリウム、トリエチルアミン、ジメチルピリジン、ジイソプロピルエチルアミン、又は1,8−ジアザビシクロ[5.4.0]ウンデカ−7−エンであり、及び/又は、前記ステップ2において、反応溶媒は、テトラヒドロフラン、2−メチルテトラヒドロフラン、N,N−ジメチルホルムアミド、アセトニトリル、又はアセトンである、請求項3に記載のイブルチニブの製造方法。
- Rはtert−ブトキシカルボニル基である、請求項5に記載のイブルチニブの製造方法。
- 前記光延反応試薬は、トリフェニルホスフィン、トリブチルホスフィン、及びトリメチルホスフィンからなる群より選ばれる第1試薬と、アゾジカルボン酸ジイソプロピル、アゾジカルボン酸−ジ−tert−ブチル、アゾジカルボン酸ジエチル、アゾジカルボン酸ジ−p−クロロベンジル、1,1’−(アゾジカルボニル)ジピペリジン、N,N,N’,N’−テトライソプロピルアゾジカルボキサミド、N,N,N’,N’−テトラメチルアゾジカルボキサミド、及び4,7−ジメチル−3,4,5,6,7,8−ヘキサヒドロ−1,2,4,7−テトラゾシン−3,8−ジオン(4,7−dimethyl−3,4,5,6,7,8−hexahydro−1,2,4,7−tetrazocin−3,8−dione)からなる群より選ばれる第2試薬とからなり、及び/又は、前記式7化合物を製造するための溶媒は、テトラヒドロフラン、N,N−ジメチルホルムアミド、ジメチルスルホキシド、N−メチルピロリドン、アセトニトリル、及び1,4−ジオキサンからなる群より選ばれ、及び/又は、前記式7化合物を脱保護する際に用いられる酸は、塩酸、臭化水素酸、硫酸、リン酸、酢酸、メタンスルホン酸、及びトリフルオロ酢酸からなる群より選ばれる、
請求項5に記載のイブルチニブの製造方法。 - イブルチニブの製造における使用のための請求項8又は9に記載の中間体化合物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510074023.1 | 2015-02-12 | ||
CN201510074023.1A CN105985343A (zh) | 2015-02-12 | 2015-02-12 | 伊布替尼的制备方法 |
CN201510074031.6 | 2015-02-12 | ||
CN201510075177.2 | 2015-02-12 | ||
CN201510074031.6A CN105985344A (zh) | 2015-02-12 | 2015-02-12 | 伊布替尼的合成方法及其中间体 |
CN201510075177.2A CN105985345A (zh) | 2015-02-12 | 2015-02-12 | 伊布替尼的制备方法及其中间体 |
PCT/CN2016/073537 WO2016127915A1 (zh) | 2015-02-12 | 2016-02-04 | 伊布替尼的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018513205A JP2018513205A (ja) | 2018-05-24 |
JP6681922B2 true JP6681922B2 (ja) | 2020-04-15 |
Family
ID=56614165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017560860A Active JP6681922B2 (ja) | 2015-02-12 | 2016-02-04 | イブルチニブの製造方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10214532B2 (ja) |
EP (1) | EP3257855B1 (ja) |
JP (1) | JP6681922B2 (ja) |
CN (2) | CN111018862B (ja) |
RU (1) | RU2712440C2 (ja) |
WO (1) | WO2016127915A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI642671B (zh) * | 2015-10-28 | 2018-12-01 | 台灣神隆股份有限公司 | 依魯替尼之製備方法及其中間體 |
CN109422752B (zh) * | 2017-09-03 | 2023-04-07 | 上海美志医药科技有限公司 | 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物 |
CN108295882B (zh) * | 2018-01-30 | 2020-07-14 | 浙江树人学院 | 核壳纳米催化剂的制备及在替尼类药物制备中的应用 |
CN113874378A (zh) | 2019-05-21 | 2021-12-31 | 詹森药业有限公司 | 用于制备btk抑制剂的方法和中间体 |
CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
CN114105990A (zh) * | 2020-08-31 | 2022-03-01 | 北京四环制药有限公司 | 一种伊布替尼的合成方法 |
CN112125913B (zh) * | 2020-10-29 | 2024-07-19 | 瑞阳制药股份有限公司 | 高纯度伊布替尼的合成方法 |
CN114516830B (zh) * | 2022-02-14 | 2023-12-19 | 兰州优莱特化学科技有限公司 | 利太膦酸的制备方法及应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2529622T3 (pl) * | 2006-09-22 | 2018-07-31 | Pharmacyclics Llc | Inhibitory kinazy tyrozynowej brutona |
EP2543375A1 (en) * | 2007-03-28 | 2013-01-09 | Pharmacyclics, Inc. | Pyrrolo-pyrimidine analogues as inhibitors of bruton's tyrosine kinase |
US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
IN2015DN00598A (ja) * | 2012-07-30 | 2015-06-26 | Concert Pharmaceuticals Inc | |
CN103121999A (zh) * | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
US10196397B2 (en) | 2014-11-19 | 2019-02-05 | Sun Pharmaceutical Industries Limited | Process for the preparation of ibrutinib |
MA41350A (fr) * | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
-
2016
- 2016-02-04 EP EP16748716.4A patent/EP3257855B1/en active Active
- 2016-02-04 CN CN201910949458.4A patent/CN111018862B/zh active Active
- 2016-02-04 RU RU2017131355A patent/RU2712440C2/ru active
- 2016-02-04 CN CN201680009639.3A patent/CN107207519B/zh active Active
- 2016-02-04 WO PCT/CN2016/073537 patent/WO2016127915A1/zh active Application Filing
- 2016-02-04 US US15/549,631 patent/US10214532B2/en active Active
- 2016-02-04 JP JP2017560860A patent/JP6681922B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN111018862B (zh) | 2021-12-24 |
EP3257855B1 (en) | 2020-04-22 |
CN111018862A (zh) | 2020-04-17 |
EP3257855A1 (en) | 2017-12-20 |
WO2016127915A1 (zh) | 2016-08-18 |
RU2017131355A (ru) | 2019-03-12 |
RU2017131355A3 (ja) | 2019-08-07 |
EP3257855A4 (en) | 2018-07-11 |
CN107207519A (zh) | 2017-09-26 |
US20180044339A1 (en) | 2018-02-15 |
CN107207519B (zh) | 2019-11-08 |
JP2018513205A (ja) | 2018-05-24 |
US10214532B2 (en) | 2019-02-26 |
RU2712440C2 (ru) | 2020-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6681922B2 (ja) | イブルチニブの製造方法 | |
JP6523566B2 (ja) | ジヒドロピリド環化合物の結晶形、製造方法および中間体 | |
CN107365275B (zh) | 高纯度的赛乐西帕 | |
CN107383017B (zh) | 依鲁替尼高效制备方法 | |
KR101272613B1 (ko) | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체 | |
JP6568221B2 (ja) | ベンゾオキサゾールオキサジンケトン系化合物の製造方法及びその中間体と結晶形 | |
CN108794491A (zh) | 一种枸橼酸托法替布的精制方法 | |
US10538504B2 (en) | Preparation method of intermediate for oxazolidinone derivative | |
CN107353291A (zh) | 一种伊布替尼的精制制备方法 | |
CN103450201B (zh) | 手性8‑(3‑氨基哌啶‑1‑基)‑黄嘌呤的制备方法 | |
JP6947354B2 (ja) | リナグリプチンの製造法 | |
CN114805327A (zh) | 一种硫代乙内酰脲药物用中间体及其制备方法与用途 | |
CN108623602B (zh) | 一种制备和纯化依鲁替尼的方法 | |
CN109153652B (zh) | 1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮的制备工艺 | |
KR20240021198A (ko) | Erk 억제제의 제조 방법 | |
KR102702677B1 (ko) | 피마살탄 및 그의 제조 중간체의 제조방법 | |
CN114539133B (zh) | 一种制备普芦卡必利中间体1-(3-甲氧基丙基)-4-哌啶胺的方法 | |
KR101959711B1 (ko) | 치환된 페닐 화합물 | |
CN110483575B (zh) | 一种阿德福韦酯的合成方法 | |
CN111153856A (zh) | 盐酸法舒地尔具有基因毒性的杂质制备方法 | |
CN106831739A (zh) | 一种用于合成依匹哌唑的制备方法 | |
CN119350434A (zh) | 一种可切割连接子Ala-Ala-Ala的工艺合成方法 | |
CN119306698A (zh) | 一种制备扎维吉泮中间体的新方法 | |
CN114685510A (zh) | 一种托法替布中间体及其制备方法 | |
CN119591537A (zh) | 一种雷芬那辛中间体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180323 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191007 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191010 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200107 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200309 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200324 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6681922 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |